Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio MergerOctober 15, 2024
Akari Therapeutics Reports Second Quarter – 2024 Financial Results and Recent HighlightsAugust 19, 2024
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic AtrophyAugust 19, 2024
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with ShareholdersJune 5, 2024
